About this trial
The core objectives of this study are to assess the short-term and long-term efficacy of auricular acupoint pressure beans combined with electroacupuncture and estazolam in the treatment of cancer-caused insomnia. The study aims to accurately compare the differences between this combination therapy and standard Western medicine in improving sleep quality and effectively alleviating anxiety and depression. Additionally, it will meticulously observe the safety of the combined treatment and record the occurrence and potential causative factors of any adverse reactions.
Eligibility criteria
Qualifiers
Age 18 and above.
The diagnosis of a malignant solid tumor was confirmed by pathological examination.
Clinically diagnosed cancer-caused insomnia with insomnia symptoms lasting more than 1 month, more than 3 or more times per week.
An Insomnia Severity Index (ISI) score of 8 or higher and meets the criteria for insomnia disorder as defined in the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition.
Disqualifiers
Irregular sleep-wake cycles in jobs with shift demands or due to inconsistent work schedules.
Inadequately treated for another sleep disorder (e.g., sleep disorder disorders such as sleep apnea obstruction syndrome, restless leg syndrome, etc.).
Received acupuncture or auricular pressure bean therapy within the past 3 months.
Estimated life expectancy is ≥3 months.
Trial design
Treatments tested in this trial
- estazolam 1-2 mg
- Auricular pressure bean combined with electroacupuncture